Jan Burger, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the long-term treatment of patients with BTK inhibitors like ibrutinib, emphasizing the importance of monitoring quality of life and side effects. He highlights the rarity of treatment resistance and notes the need for frequent check-ups to assess cardiovascular side effects. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Monitoring patients with CLL on ibrutinib-based therapies
Теги
Speaker: Jan BurgerInstitution: University of Texas MD Anderson Cancer CenterEvent: ERIC 2024Format: InterviewSubject: Chronic Lymphocytic LeukemiaSubject: LeukemiaField: Community FocusMedicines: BTK inhibitorsMedicines: Ibrutinibcardio-oncologycardiovascular side effectsQoLquality of lifeAEsside effectsatrial fibrillationbleeding complicationshypertensionpatient monitoringField: Treatment
